Kagoshima Collaborate Trial in Metabolic Syndrome (KACT Study) (KACT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00790946|
Recruitment Status : Unknown
Verified December 2008 by Kagoshima University.
Recruitment status was: Recruiting
First Posted : November 14, 2008
Last Update Posted : June 3, 2010
Information provided by:
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Unknown|
|Estimated Primary Completion Date :||December 2009|
|Estimated Study Completion Date :||December 2009|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Miyata M, Ikeda Y, Nakamura S, Sasaki T, Abe S, Minagoe S, Torii H, Lee S, Tateishi S, Kihara K, Ohba I, Kajiya S, Furusho Y, Hamasaki S, Tei C; Kagoshima Collaborate Trial in Metabolic Syndrome (KACT-MetS) Investigators. Effects of valsartan on fibrinolysis in hypertensive patients with metabolic syndrome. Circ J. 2012;76(4):843-51.